{
  "report_rows": [
    {
      "kpi": "Q2 2026 AFFO per diluted share",
      "prediction": "IN-LINE",
      "answer": "pred ~$0.62 vs. cons $0.62",
      "confidence": "HIGH"
    },
    {
      "kpi": "Q2 2026 total revenue",
      "prediction": "BEAT",
      "answer": "pred ~$1.055B vs. cons $1.040B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 adjusted EBITDA",
      "prediction": "IN-LINE",
      "answer": "pred ~$872M vs. cons $865M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "AFFO per diluted share",
      "prediction": "BETTER",
      "answer": "guide ~$2.465 midpoint vs. cons $2.46 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "AFFO attributable to common stockholders",
      "prediction": "BETTER",
      "answer": "guide ~$2.690B midpoint vs. cons $2.683B (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 1.4,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.6,
  "day5_path": "FADE",
  "day5_rationale": "Day-1 residual +1.4% fades to a +0.6% five-day residual because the modest revenue beat and small FY2026 guidance increase support the stock initially, but limited per-share upside versus the $2.46 consensus\u2014after acquisition-related dilution and refinancing costs\u2014leaves out-period estimate revisions small.",
  "day5_confidence": "MEDIUM"
}